2227 GMT - Healius's recent performance by its pathology business underwhelms Citi. Healius indicates profitability of Pathology division in 1H would be broadly in line with the same period a year earlier. That implies some A$4 million Ebit, well below Citi's A$14 million forecast and an even bigger miss to consensus hopes. It also comes despite a 5.9% improvement in revenue in FY 2025 so far. Healius says it has faced labor cost rises and is investing to keep its revenue growing. "Healius believes its share has stabilized in the last six months, albeit it seems to have come at a cost to profitability," says analyst Mathieu Chevrier. Citi retains a sell call on Healius's stock. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
November 17, 2024 17:27 ET (22:27 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。